tiprankstipranks
Trending News
More News >
Sangamo Biosciences (SGMO)
NASDAQ:SGMO
US Market
Advertisement

Sangamo Biosciences (SGMO) Stock Forecast & Price Target

Compare
2,382 Followers
See the Price Targets and Ratings of:

SGMO Analyst Ratings

Moderate Buy
6Ratings
Moderate Buy
4 Buy
2 Hold
0 Sell
Based on 6 analysts giving stock ratings to
Sangamo
Biosciences
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

SGMO Stock 12 Month Forecast

Average Price Target

$4.10
▲(754.17%Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Sangamo Biosciences in the last 3 months. The average price target is $4.10 with a high forecast of $10.00 and a low forecast of $1.50. The average price target represents a 754.17% change from the last price of $0.48.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","8":"$8","11":"$11","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2,5,8,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.54,1.267692307692308,1.9953846153846155,2.723076923076923,3.450769230769231,4.178461538461539,4.906153846153846,5.633846153846155,6.361538461538462,7.0892307692307694,7.816923076923078,8.544615384615387,9.272307692307692,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.54,0.8138461538461539,1.0876923076923077,1.3615384615384614,1.6353846153846152,1.909230769230769,2.1830769230769227,2.4569230769230765,2.7307692307692304,3.0046153846153842,3.278461538461538,3.552307692307692,3.8261538461538454,{"y":4.1,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.54,0.6138461538461539,0.6876923076923077,0.7615384615384615,0.8353846153846154,0.9092307692307693,0.9830769230769231,1.0569230769230769,1.1307692307692307,1.2046153846153846,1.2784615384615385,1.3523076923076922,1.426153846153846,{"y":1.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.33,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.7,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.85,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.82,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.88,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.36,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.02,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.23,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.02,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.57,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.47,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.54,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$10.00Average Price Target$4.10Lowest Price Target$1.50
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on SGMO
TipRanks AITipRanks
Not Ranked
TipRanks
$0.5
Hold
4.17%
Upside
Reiterated
07/08/25
The overall stock score for Sangamo Biosciences is driven by severe financial challenges, including declining revenue and negative cash flows, coupled with weak technical signals. Although there are strategic collaborations and positive trial results, significant financial and regulatory risks persist, limiting the stock's attractiveness.
TD Cowen Analyst forecast on SGMO
Ritu BaralTD Cowen
TD Cowen
Buy
Reiterated
06/30/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: Sangamo Biosciences (NASDAQ: SGMO), Pliant Therapeutics (NASDAQ: PLRX) and Stevanato Group (NYSE: STVN)
H.C. Wainwright Analyst forecast on SGMO
Patrick TrucchioH.C. Wainwright
H.C. Wainwright
$10
Buy
1983.33%
Upside
Reiterated
06/30/25
Analysts' Top Healthcare Picks: Sangamo Biosciences (SGMO), Alpha Cognition Inc (ACOG)
Wells Fargo Analyst forecast on SGMO
Yanan ZhuWells Fargo
Wells Fargo
$2
Hold
316.67%
Upside
Reiterated
06/25/25
Cautious Optimism for Sangamo Biosciences Amid Promising Fabry Program Data and Ongoing Business Developments
Barclays Analyst forecast on SGMO
Gena WangBarclays
Barclays
$9$5
Buy
941.67%
Upside
Reiterated
05/14/25
Analysts Offer Insights on Healthcare Companies: Sangamo Biosciences (NASDAQ: SGMO), UnitedHealth (NYSE: UNH) and Adaptimmune Therapeutics (NASDAQ: ADAP)
Jefferies
$2$1.5
Buy
212.50%
Upside
Reiterated
05/13/25
Sangamo BioSciences (SGMO) PT Lowered to $1.50 at JefferiesJefferies analyst Maury Raycroft lowered the price target on Sangamo BioSciences (NASDAQ: SGMO) to $1.50 (from $2.00) while maintaining a Buy rating.
RBC Capital Analyst forecast on SGMO
Luca IssiRBC Capital
RBC Capital
$2
Hold
316.67%
Upside
Reiterated
05/13/25
RBC Capital Keeps Their Hold Rating on Sangamo Biosciences (SGMO)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on SGMO
TipRanks AITipRanks
Not Ranked
TipRanks
$0.5
Hold
4.17%
Upside
Reiterated
07/08/25
The overall stock score for Sangamo Biosciences is driven by severe financial challenges, including declining revenue and negative cash flows, coupled with weak technical signals. Although there are strategic collaborations and positive trial results, significant financial and regulatory risks persist, limiting the stock's attractiveness.
TD Cowen Analyst forecast on SGMO
Ritu BaralTD Cowen
TD Cowen
Buy
Reiterated
06/30/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: Sangamo Biosciences (NASDAQ: SGMO), Pliant Therapeutics (NASDAQ: PLRX) and Stevanato Group (NYSE: STVN)
H.C. Wainwright Analyst forecast on SGMO
Patrick TrucchioH.C. Wainwright
H.C. Wainwright
$10
Buy
1983.33%
Upside
Reiterated
06/30/25
Analysts' Top Healthcare Picks: Sangamo Biosciences (SGMO), Alpha Cognition Inc (ACOG)
Wells Fargo Analyst forecast on SGMO
Yanan ZhuWells Fargo
Wells Fargo
$2
Hold
316.67%
Upside
Reiterated
06/25/25
Cautious Optimism for Sangamo Biosciences Amid Promising Fabry Program Data and Ongoing Business Developments
Barclays Analyst forecast on SGMO
Gena WangBarclays
Barclays
$9$5
Buy
941.67%
Upside
Reiterated
05/14/25
Analysts Offer Insights on Healthcare Companies: Sangamo Biosciences (NASDAQ: SGMO), UnitedHealth (NYSE: UNH) and Adaptimmune Therapeutics (NASDAQ: ADAP)
Jefferies
$2$1.5
Buy
212.50%
Upside
Reiterated
05/13/25
Sangamo BioSciences (SGMO) PT Lowered to $1.50 at JefferiesJefferies analyst Maury Raycroft lowered the price target on Sangamo BioSciences (NASDAQ: SGMO) to $1.50 (from $2.00) while maintaining a Buy rating.
RBC Capital Analyst forecast on SGMO
Luca IssiRBC Capital
RBC Capital
$2
Hold
316.67%
Upside
Reiterated
05/13/25
RBC Capital Keeps Their Hold Rating on Sangamo Biosciences (SGMO)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sangamo Biosciences

1 Month
xxx
Success Rate
7/19 ratings generated profit
37%
Average Return
-5.42%
reiterated a xxx
rating 19 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 36.84% of your transactions generating a profit, with an average return of -5.42% per trade.
3 Months
xxx
Success Rate
7/19 ratings generated profit
37%
Average Return
+2.50%
reiterated a xxx
rating 19 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 36.84% of your transactions generating a profit, with an average return of +2.50% per trade.
1 Year
Gena WangBarclays
Success Rate
8/19 ratings generated profit
42%
Average Return
+9.67%
reiterated a buy rating 2 months ago
Copying Gena Wang's trades and holding each position for 1 Year would result in 42.11% of your transactions generating a profit, with an average return of +9.67% per trade.
2 Years
xxx
Success Rate
6/19 ratings generated profit
32%
Average Return
+3.37%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 31.58% of your transactions generating a profit, with an average return of +3.37% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SGMO Analyst Recommendation Trends

Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
5
3
8
8
7
Buy
2
3
5
6
5
Hold
5
4
4
5
5
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
12
10
17
19
17
In the current month, SGMO has received 12 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. SGMO average Analyst price target in the past 3 months is 4.10.
Each month's total comprises the sum of three months' worth of ratings.

SGMO Financial Forecast

SGMO Earnings Forecast

Next quarter’s earnings estimate for SGMO is -$0.01 with a range of -$0.17 to $0.24. The previous quarter’s EPS was -$0.14. SGMO beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.16% of the time in the same period. In the last calendar year SGMO has Preformed in-line its overall industry.
Next quarter’s earnings estimate for SGMO is -$0.01 with a range of -$0.17 to $0.24. The previous quarter’s EPS was -$0.14. SGMO beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.16% of the time in the same period. In the last calendar year SGMO has Preformed in-line its overall industry.

SGMO Sales Forecast

Next quarter’s sales forecast for SGMO is $31.68M with a range of $400.00K to $100.00M. The previous quarter’s sales results were $6.44M. SGMO beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.50% of the time in the same period. In the last calendar year SGMO has Preformed in-line its overall industry.
Next quarter’s sales forecast for SGMO is $31.68M with a range of $400.00K to $100.00M. The previous quarter’s sales results were $6.44M. SGMO beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.50% of the time in the same period. In the last calendar year SGMO has Preformed in-line its overall industry.

SGMO Stock Forecast FAQ

What is SGMO’s average 12-month price target, according to analysts?
Based on analyst ratings, Sangamo Biosciences’s 12-month average price target is 4.10.
    What is SGMO’s upside potential, based on the analysts’ average price target?
    Sangamo Biosciences has 754.17% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is SGMO a Buy, Sell or Hold?
          Sangamo Biosciences has a consensus rating of Moderate Buy which is based on 4 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Sangamo Biosciences’s price target?
            The average price target for Sangamo Biosciences is 4.10. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $10.00 ,the lowest forecast is $1.50. The average price target represents 754.17% Increase from the current price of $0.48.
              What do analysts say about Sangamo Biosciences?
              Sangamo Biosciences’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of SGMO?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis